Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In addition, it develops KOSTAIVE, a self-amplifying RNA vaccine for COVID-19; ARCT-2138 (LUNAR-FLU), which is in Phase1 clinical trial for the treatment of seasonal influenza; and ARCT-2304 (LUNAR-H5N1) that is in Phase1 clinical trial for the treatment of Pandemic Influenza. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
Pipeline Progress | Learn about Arcturus' advancing clinical trials in cystic fibrosis and OTC deficiency, with interim data expected to shape the company's future prospects |
Strategic Partnerships | Delve into Arcturus' collaborations with CSL Seqirus and Meiji, positioning the company for significant revenue potential in vaccine distribution |
Financial Outlook | Analysts project sales decline but extended cash runway to 2028. Average price target ranges from $41 to $140, reflecting diverse market perspectives |
mRNA Pionee | Explore Arcturus Therapeutics' innovative self-amplifying mRNA technology and its potential to revolutionize therapeutics and vaccines |
Metrics to compare | ARCT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipARCTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −3.8x | −4.3x | −0.5x | |
PEG Ratio | −0.19 | 0.09 | 0.00 | |
Price / Book | 1.2x | 2.5x | 2.6x | |
Price / LTM Sales | 3.0x | 11.0x | 3.2x | |
Upside (Analyst Target) | 136.2% | 46.0% | 47.6% | |
Fair Value Upside | Unlock | 2.7% | 6.1% | Unlock |